Company: PACB
Filing Date: 2025-03-17
Form Type: 10-K
Source: 0001299130-25-000061
Chunk: 875

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-03-17
Form: 10-K
Item: Item 3
Chunk 875
---
,319 11,230 Payment of debt issuance costs— (7,375)— Payment of contingent consideration— (86,411)— 

Fiscal 2024 Form 10-K88

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.CONSOLIDATED STATEMENTS OF CASH FLOWSPayments made in conjunction with convertible notes exchange(50,200)— — Notes payable principal payoff (490)(1,842)(1,608)Net cash (used in) provided by financing activities (42,987)108,891 9,622 Net decrease in cash, cash equivalents, and restricted cash(125,041)(145,678)(137,506)Cash, cash equivalents, and restricted cash at beginning of period 182,633 328,311 465,817 Cash, cash equivalents, and restricted cash at end of period $57,592 $182,633 $328,311 Cash and cash equivalents at end of period 55,370 179,911 325,089 Restricted cash at end of period 2,222 2,722 3,222 Cash, cash equivalents, and restricted cash at end of period $57,592 $182,633 $328,311  Supplemental disclosure of cash flow informationInterest paid$14,805 $15,687 $14,049 Supplemental disclosure of non-cash investing and financing activitiesInventory transferred to property and equipment $4,194 $3,984 $2,812 Property and equipment transferred to inventory$(2,572)$(7,022)$(715)Right-of-use asset and liability additions and modifications$18,253 $— $— Issuance of common stock in conjunction with convertible notes exchange$36,199 $— $— Issuance of common stock in acquisition of Apton and Omniome$— $76,642 $— Issuance of common stock in connection with Apton liquidity event bonus plan$— $2,111 $— Convertible notes exchange$— $441,000 $— Issuance of common stock following milestone achievement$— $84,761 $—     

See accompanying notes to the consolidated financial statements.

Fiscal 2024 Form 10-K89

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.NOTES TO CONS